Skip to main content

Lawsuit Alleges GBCAs Cause Disabling Injuries

Lawsuit Alleges GBCAs Cause Disabling Injuries

Lawsuit Alleges GBCAs Cause Disabling Injuries

Introduction

In a complaint filed by a plaintiff in the U.S. District Court for the Eastern District of Louisiana, she suffered an allergic reaction in July 2018, after being injected with various gadolinium-based contrast agents during a lumbar spine MRI and CT scan of her abdomen and pelvis.

In her complaint, the plaintiff named GE Healthcare, Bayer, Tyco Healthcare, Mallinckrodt, Inc., and Bracco Diagnostics as defendants who manufactures gadolinium-based contrast dyes such as Omniscan, Magnevist, Gadavist, MultiHance, Dotarem, ProHance, OptiMARK, Eovist, and Ablavar. The plaintiff was re-admitted to the hospital numerous times owing to the continued complications from the IV dye. The lawsuit stated, “upon information and belief, the GBCAs produced by Manufacturing Defendants and used by Petitioner is defective in its design or formulation in that it is not reasonably fit, suitable, or safe for its intended purpose and/or its foreseeable risks exceeded the benefits associated with its design and formulation.” The Louisiana woman claimed that she suffered severe, disabling, and disfiguring injuries as side-effects of the IV injection.

The lawsuit filed by the plaintiff will join the growing number of gadolinium contrast dye lawsuits filed in several state courts nationwide, and the litigation is expected to expand in the coming months.

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

NC to Get $150M to Boost Opioid Treatment, Recovery

Categories: Opioids

North Carolina will receive an additional $150 million from Purdue Pharma and the Sackler family as part of a national $7.4 billion settlement related to the opioid

SRI Gets FDA OK for High-Dose Naloxone Trial

Categories: Opioids

SRI has received authorization from the U.S. Food and Drug Administration (FDA) to begin Phase 1 clinical trials of a new, high-dose injectable naloxone formulation.

The approval was granted under an Investigational New Drug (IND)…

Spokane County to Get $5M in New Opioid Settlement

Categories: Opioids

Jurisdictions within Spokane County are set to receive nearly $4.7 million as part of a sweeping $7.4 billion nationwide settlement with Purdue Pharma and its owners, the Sackler family.

The agreement addresses the company’s role in fueling…

✍️ FREE—3000 Pages Medical Record Review Trial!                
No Contract. No Risk—Fully Customized, Free!

Only 10 Firms Accepted—Offer Ends June 30!